Embolism News and Research

RSS

Avoiding overtesting in the emergency department could create significant health care savings

An emergency department is sometimes the first place a person thinks to go for health care.

27 Jun 2019

More screening and new treatments needed for sickle cell disease

The promise of new treatments for sickle cell disease, a group of inherited red blood cell disorders, has never been so great, but it will only be realized if there is constant investment in health policies such as programs for screening newborns, especially in sub-Saharan Africa, where most cases occur.

13 Jun 2019

CDC says large number of pregnancy related deaths could be prevented

The Centres for Disease Prevention and Control (CDC) has released a Vital Signs report that says that at least three in five pregnancy related deaths are preventable.

8 May 2019

HORIBA Medical introduces D-Dimer reagent for Yumizen G hemostasis range

HORIBA UK Ltd, Medical announces the launch of a D-Dimer parameter for its Yumizen G hemostasis range of instruments.

From HORIBA Medical 25 Mar 2019

Study reveals increase in adverse outcomes for people taking aspirin and warfarin

A daily aspirin is a commonly used, generally safe therapy for people who need help preventing heart attacks or stroke.

5 Mar 2019

New collaboration aims to prevent life-threatening adverse reactions to medications

The University of Arizona College of Medicine - Phoenix and Banner Health are collaborating to prevent life-threatening adverse reactions to medications.

27 Feb 2019

New PET/CT tracer shows high detection rate for diagnosis of acute venous thromboembolism

A first-in-human study featured in the February issue of The Journal of Nuclear Medicine reports that the novel positron emission tomography/computed tomography tracer 18F-GP1 showed excellent image quality and a high detection rate for the diagnosis of acute venous thromboembolism.

18 Feb 2019

Scientists show treatment success in minimally invasive heart valve procedure

Scientists at the Center for Cardiology of the Mainz University Medical Center have examined the success of more than 13,575 minimally invasive procedures on the mitral valve in the largest study of their kind to date.

5 Feb 2019

Ketogenic supplementation can reduce seizures without dietary restriction, suggests study

The ketogenic diet has proven successful in helping people lose weight and improve their overall health, including those with epilepsy. The low-carb diet transitions the body from burning sugar to burning fat and ketones for energy.

8 Jan 2019

New study adds evidence to efficacy and safety of low-dose vaginal estrogen

Despite its proven effectiveness in treating the genital symptoms of menopause, low-dose vaginal estrogen therapy remains underused largely because of misperceptions regarding its safety.

19 Dec 2018

Oral drug used to treat blood clots in cancer patients appears to be safe and effective

Mayo Clinic researchers have found that an oral drug, apixaban, used to treat blood clots in patients undergoing cancer therapy, is safe and effective.

4 Dec 2018

New clinical practice guidelines for managing venous thromboembolism released

Venous thromboembolism, a term referring to blood clots in the veins, is a highly prevalent and far-reaching public health problem that can cause disability and death.

28 Nov 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

New standard of care aims to prevent deaths caused by largely preventable blood clots

A new nationally agreed standard of care released today (Thursday) aims to reduce the tens of thousands of Australian lives put at risk each year by largely preventable blood clots, which kill four times more people than road accidents.

12 Oct 2018

‘Grossly unfair’? Widower takes ban on military injury claims to Supreme Court

More than four years after Navy Lt. Rebekah Daniel bled to death within hours of childbirth at a Washington state military hospital, her husband still doesn't know exactly how — or why — it happened.

11 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Recurrence risk of VTE appears similar for patients with cancer and those with unprovoked VTE

Patients with venous thromboembolism carry a high risk of recurrence. Accordingly, a 16-year Danish prospective cohort study of nearly 74,000 patients with incident VTE concluded that the risk of recurrence is substantial.

25 Sep 2018

Embolism News and Research

Avoiding overtesting in the emergency department could create significant health care savings

More screening and new treatments needed for sickle cell disease

CDC says large number of pregnancy related deaths could be prevented

HORIBA Medical introduces D-Dimer reagent for Yumizen G hemostasis range

Study reveals increase in adverse outcomes for people taking aspirin and warfarin

New collaboration aims to prevent life-threatening adverse reactions to medications

New PET/CT tracer shows high detection rate for diagnosis of acute venous thromboembolism

Scientists show treatment success in minimally invasive heart valve procedure

Ketogenic supplementation can reduce seizures without dietary restriction, suggests study

New study adds evidence to efficacy and safety of low-dose vaginal estrogen

Oral drug used to treat blood clots in cancer patients appears to be safe and effective

New clinical practice guidelines for managing venous thromboembolism released

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

New standard of care aims to prevent deaths caused by largely preventable blood clots

‘Grossly unfair’? Widower takes ban on military injury claims to Supreme Court

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Recurrence risk of VTE appears similar for patients with cancer and those with unprovoked VTE

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News